Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Selexipag - Actelion/Nippon Shinyaku

Drug Profile

Selexipag - Actelion/Nippon Shinyaku

Alternative Names: ACT-293987; JNJ-678896049; NS-304; Uptravi

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nippon Shinyaku
  • Developer Actelion Pharmaceuticals; Nippon Shinyaku
  • Class Acetamides; Amines; Anti-inflammatories; Antithrombotics; Pyrazines; Small molecules; Sulfonamides; Vascular disorder therapies; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension; Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension; Pulmonary hypertension
  • Phase III Arteriosclerosis obliterans
  • Clinical Phase Unknown Thromboangiitis obliterans
  • No development reported Raynaud's disease
  • Discontinued Spinal stenosis

Most Recent Events

  • 19 May 2023 Pooled efficacy data from the phase III GRIPHON, SERAPHIN and COMPASS-2 trials in Pulmonary arterial hypertension presented at the 119th International Conference of the American Thoracic Society (ATS-2023)
  • 19 Apr 2023 Actelion completes a phase II/III trial for Pulmonary arterial hypertension in USA, UK, Netherlands, Hungary, Germany, Poland, Spain, Belgium, Canada, France and Italy (NCT03942211) (EudraCT2018-004887-74)
  • 28 Feb 2023 No recent reports of development identified for phase-I development in Pulmonary-arterial-hypertension(In volunteers) in Belgium (PO, Controlled release)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top